MAO-B
6 drugs CNS
3
approved indications
6
Approved Drugs
6
Companies
4
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 6 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (4 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
AVID RADIOPHARMS INC 1 drug
ORBION PHARMS 1 drug
BAUSCH 1 drug
By Therapeutic Area
CNS 6 drugs
Drugs by Company PRO
AVID RADIOPHARMS INC 1 drug
ORBION PHARMS 1 drug
BAUSCH 1 drug
PRINSTON INC 1 drug
Teva 1 drug
MDD US 1 drug
By Therapeutic Area
CNS 6 drugs
TAUVID, RASAGILINE MESYLATE, ZELAPAR, SAFINAMIDE MESYLATE +2 more
Indications Treated
Parkinson's DiseaseAlzheimer's DiseaseChronic Traumatic EncephalopathyCognitive Impairment
All Drugs Targeting MAO-B
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| TAUVID | AVID RADIOPHARMS INC | 2020 | 3 | CNS |
| RASAGILINE MESYLATE | ORBION PHARMS | 2013 | 1 | CNS |
| ZELAPAR | BAUSCH | 2006 | 1 | CNS |
| SAFINAMIDE MESYLATE | PRINSTON INC | 2023 | 1 | CNS |
| AZILECT | Teva | 2006 | 1 | CNS |
| XADAGO | MDD US | 2017 | 1 | CNS |